Tempus AI, Inc. Class A ( (TEM) ) has released its Q2 earnings. Here is a breakdown of the information Tempus AI, Inc. Class A presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tempus AI, Inc. is a technology company specializing in artificial intelligence to enhance precision medicine and patient care, primarily operating in the healthcare sector with a focus on genomics and data services.
In its second quarter of 2025, Tempus AI reported a significant increase in revenue, reaching $314.6 million, an 89.6% rise compared to the previous year, driven by substantial growth in its genomics and data services segments.
The company saw genomics revenue surge by 115.3% year-over-year, largely due to increased volumes in oncology and hereditary testing. Data and services revenue also grew by 35.7%, with data licensing leading the charge. Tempus AI’s gross profit rose by 158.3% to $195 million, and the company issued $750 million in convertible senior notes to enhance financial flexibility.
Tempus AI is optimistic about its future, raising its full-year revenue guidance to $1.26 billion and aiming for a positive adjusted EBITDA of $5 million. The company continues to innovate, expanding its AI-powered clinical tools and advancing its monitoring capabilities, positioning itself well for future growth.
Looking ahead, Tempus AI remains focused on leveraging its AI capabilities to drive further advancements in precision medicine, with management expressing confidence in achieving sustained growth and profitability.